- Conditions
- Hypogonadism
- Interventions
- Testosterone undecanoate, Testosterone enanthate
- Drug
- Lead sponsor
- Clarus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 445
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic
- Interventions
- Soquelitinib, Placebo
- Drug
- Lead sponsor
- Corvus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- South San Francisco, California
- Conditions
- Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
- Interventions
- tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more
- Conditions
- SARS CoV 2 Infection
- Interventions
- ASC10, Placebo
- Drug
- Lead sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Anniston, Alabama • Hialeah, Florida
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Imatinib, Sildenafil, Bosentan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Weston, Florida • Mineola, New York
- Conditions
- Recurrent Glioma
- Interventions
- Bevacizumab, Minocycline, Radiation
- Drug · Radiation
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Intermittent Claudication
- Interventions
- Cilostazol 100 mg, PMR 200 mg
- Drug
- Lead sponsor
- Genovate Biotechnology Co., Ltd.,
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- HIV-1 Infection
- Interventions
- Bevirimat
- Drug
- Lead sponsor
- Myrexis Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- San Francisco, California • Fort Lauderdale, Florida • Atlanta, Georgia + 1 more
- Conditions
- Iron Deficiency Anaemia, Chronic Kidney Disease
- Interventions
- FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
- Drug
- Lead sponsor
- Vifor Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Solid Tumors
- Interventions
- Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 920 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 32
- States / cities
- Goodyear, Arizona • Los Angeles, California • Newport Beach, California + 25 more
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Interventions
- TAK-935, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
- Conditions
- Telomere Disease
- Interventions
- Danazol
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 3 Years to 99 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer
- Interventions
- Gemcitabine, Sorafenib, Placebo, Capecitabine
- Drug
- Lead sponsor
- Accelerated Community Oncology Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 44
- States / cities
- Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 37 more
- Conditions
- Neoplasms
- Interventions
- Sorafenib (Nexavar, BAY43-9006)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • San Antonio, Texas
- Conditions
- Meniere's Disease
- Interventions
- SPI-1005
- Drug
- Lead sponsor
- Sound Pharmaceuticals, Incorporated
- Industry
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 5
- States / cities
- Los Angeles, California • New York, New York • Charleston, South Carolina + 1 more
- Conditions
- Hepatitis C
- Interventions
- GS-9669 tablets, Placebo to Match GS-9669 tablet
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 10
- States / cities
- Los Angeles, California • DeLand, Florida • Orlando, Florida + 6 more
- Conditions
- Human Immunodeficiency Virus Infection
- Interventions
- lopinavir/ritonavir (LPV/r), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), raltegravir (RAL)
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Atlantis, Florida + 11 more
- Conditions
- 22q11.2 Deletion Syndrome
- Interventions
- NFC-1
- Drug
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Myelogenous Leukemia in Chronic Phase
- Interventions
- Nilotinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 32
- States / cities
- Anaheim, California • Burbank, California • Concord, California + 27 more
- Conditions
- Autistic Disorder
- Interventions
- Pregnenolone
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Hepatitis C
- Interventions
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 19 more
- Conditions
- Hepatitis C
- Interventions
- Alisporivir, Boceprevir, Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Baltimore, Maryland
- Conditions
- Type 1 Diabetes Mellitus, Hypoglycemia
- Interventions
- Allogeneic Islets of Langerhans, Everolimus, anti-thymocyte globulin, Cyclosporine
- Biological · Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hypogonadism
- Interventions
- Oral testosterone undecanoate (TU) (300 mg T equivalents/dose), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
- Drug
- Lead sponsor
- Clarus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 68 Years · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Antonio, Texas